Hold Cipla

Hold CiplaStock market analyst Rajesh Tambe of Sunchan Securities is of the view that investors can 'hold' Cipla Ltd stock.

He said that Cipla is fundamentally very strong and one of the best bets in the pharmaceutical segment.

Today, the stock opened at Rs 321.75 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 363 and a low of Rs 218.25 on BSE.

Current EPS & P/E ratio stood at 12.29 and 25.79 respectively.

Cipla's Q4 net sales remained up by 6.66% at Rs 1,317.5 crore as compared to Rs 1,235.2 crore, year-on-year (YoY).

The company's net profit surged 8.94% at Rs 275.5 crore as against Rs 252.9 crore, YoY.

During the last fiscal, Cipla recorded an increase of 7% in income from operations. During the fourth quarter, the company's domestic sales climbed 9% and exports sales remained up by about 5%.

Moreover, the reports said that Cipla is getting hold of two plants, which were mainly manufacturing formulations and bulk drugs/intermediates for the company, for an around Rs 82 crore.

The deal has already got directors' approval.

The first plant located at Sikkim will be purchased for Rs 51.38 crore.

The other formulations manufacturing facility situated at Kurkumbh (Pune) will be bought for Rs 30.64 crore.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate